Clinical Trial Update: This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload. [Phase 4]

View source ↗

Summary

Phase 4 trial by Novartis evaluated the efficacy and safety of deferasirox in patients with myelodysplastic syndrome, thalassemia, and transfusion-related iron …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome
• Thalassemia

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myelodysplastic Syndrome, Thalassemia | Phase 4 | Status: COMPLETED